By playing, you agree to uListen's Terms and Privacy Policy and YouTube's Terms of Service.
Peter Attia MD255-Latest therapeutics in CVD, APOE’s role in Alzheimer’s disease, familial hypercholesterolemia
Summaries, chapters, transcripts, and FAQs on this page are made by uListen, not YouTube.
At a glance
WHAT IT’S REALLY ABOUT
FH genetics, CETP inhibitor comeback, and apoE mechanisms in disease
- John Kastelein explains familial hypercholesterolemia (FH) as an autosomal dominant condition with near-complete penetrance where LDL is elevated from birth and can lead to early, often fatal coronary events if untreated.
- He describes how FH is diagnosed clinically through family history and isolated high LDL with secondary causes excluded, but emphasizes that genetic testing clarifies ambiguous cases due to LDL overlap between affected and unaffected relatives.
- He outlines FH treatment across the lifespan, including statin initiation in childhood, escalation to combination lipid-lowering therapy in adults, and advanced options for severe heterozygous and homozygous FH.
- Kastelein reviews the “sordid” history of CETP inhibitors, arguing that prior failures largely reflected off-target toxicity or reliance on HDL changes rather than sufficient LDL/ApoB lowering.
- He presents obicetrapib as a highly potent CETP inhibitor in phase 3 development, discussing early safety/tolerability, strong LDL lowering, notable Lp(a) reductions, and mechanistic hypotheses linking CETP inhibition, APOA1, APOE4, and Alzheimer biology.
IDEAS WORTH REMEMBERING
5 ideasFamilial hypercholesterolemia is an early-onset, high-penetrance genetic driver of premature ASCVD.
He explains FH as a highly penetrant autosomal dominant condition where LDL is elevated from birth, leading to early cholesterol deposition (tendon xanthomas, arcus cornealis, xanthelasmata) and a high risk of premature, often proximal, coronary events if untreated.
Genetic testing resolves the LDL-overlap problem and is especially informative when diagnosis is anchored in children.
He says clinical diagnosis relies on family history of premature coronary disease plus isolated elevated LDL (with normal triglycerides/HDL and secondary causes excluded), but notes overlap in LDL levels between affected and unaffected relatives; in their pediatric cohort with clear inheritance patterns, sequencing found mutations in ~95% of cases.
Different FH genes converge on one pathway: reduced LDL receptor–mediated clearance at the liver.
He describes the core mechanism as impaired hepatic clearance of LDL particles: ApoB binding defects, LDL receptor defects, or PCSK9 gain-of-function all reduce effective LDL receptor–mediated uptake, converging on the same phenotype of high LDL.
They treat FH aggressively from childhood—statins early, with lifestyle as supportive—not curative.
He outlines their pediatric approach: lifestyle counseling (including anti-smoking) but starting statins as early as age six; he notes they historically used pravastatin first, now broader statin use, sometimes adding ezetimibe, while acknowledging guideline targets like LDL <130 in children reflect conservatism rather than biology.
Modern FH care is combination therapy, yet a meaningful minority remain hard to treat even with multiple agents.
In adults (and in severe cases), he describes escalation to combination therapy (statin + ezetimibe + PCSK9 monoclonals; inclisiran as part of adult management) and, for homozygous FH, adding evinacumab; he notes a subset of “severe heterozygous FH” still doesn’t reach low LDL despite triple therapy.
WORDS WORTH SAVING
5 quotesFH is a true autosomal dominant disease, meaning it, it's not sex-linked. Uh, you don't need two parents to get it. You only need one parent to get it. It's almost 100% penetrant, meaning that if you have a robust mutation in one of the genes that cause FH, you're almost certain to get the phenotype, and the phenotype starts very early.
— John Kastelein
It's not great science, but there are some indications, but most of that work is done preclinically.
— John Kastelein
If you're a man and you smoke and you have FH, it's a death sentence if you're not treated.
— John Kastelein
If you don't understand a side effect in phase two, you don't move a drug into phase three until you've understood it.
— John Kastelein
APOE4 is an insufficient molecule to get cholesterol out of cells in the brain that have too much or bring cholesterol to cells in the brain that have too little. So it fails on both accounts.
— John Kastelein
High quality AI-generated summary created from speaker-labeled transcript.
